Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its proprietary PDAOAI drug discovery and development platform will be featured during the Product & Engineering keynote at Qdrant Vector Space Day 2026, scheduled for June 11 in San Francisco. Company executives will join Qdrant leadership to discuss how PDAOAI, operating on Qdrant infrastructure, has helped accelerate the development of two drug candidates from concept to investigational new drug filings in less than two years, significantly reducing the time and cost traditionally associated with pharmaceutical development.
The presentation will highlight several innovations underpinning the platform, including a proprietary “manifold folding” technique designed to improve semantic retrieval accuracy and reduce large language model hallucinations, as well as the indexing of approximately 28 million PubMed biomedical abstracts on Qdrant Cloud. Oncotelic said the platform leverages advanced vector search technologies to support large-scale biomedical research and accelerate oncology drug discovery efforts.
This announcement is significant because it demonstrates a concrete application of artificial intelligence in drug discovery that has already yielded tangible results. By cutting the timeline from concept to IND filing to under two years—compared to the industry average of several years—the PDAOAI platform could transform how pharmaceutical companies approach early-stage development. For investors, this suggests that Oncotelic may be able to bring therapies to market faster and at lower cost, potentially improving its competitive position in the oncology space.
The implications extend beyond Oncotelic. If the platform’s capabilities are widely adopted, the entire drug development process could become more efficient, reducing the financial burden on biotech firms and ultimately leading to more affordable treatments for patients. The use of Qdrant’s vector search technology to index millions of biomedical abstracts also highlights the growing role of AI in managing and analyzing vast scientific datasets.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. The company also benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. For more information, visit https://ibn.fm/OTLC.
